EnteroBiotix begins phase 2 trial of IBS treatment
Betsy Goodfellow | April 3, 2024 | News story | Research and Development | EnteroBiotix, Gastrointestinal tract, IBS, irritable bowel syndrome
EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which is intended to assess EBX-102-02 for the treatment of patients with irritable bowel disease (IBS).
The phase 2 TrIuMPH study will enroll 60 patients with IBS and constipation across sites in the UK, with the primary objective of evaluating the safety and tolerability of EBX-102-02. The trial’s secondary and exploratory endpoints include assessing preliminary signals of efficacy of the drug and potential biomarkers over a six-week period.
The trial is being conducted in collaboration with the Functional Gut Clinic, and utilises EnteroBiotix’s proprietary AMPLA technology.
According to the company’s press release, ‘EBX-102-02 is a next-generation, full-spectrum drug candidate that contains highly diverse microbial ecosystems and key functional groups that restore and fortify the microbiome. EBX-102-02 is presented as an easy to take capsule containing off-white colour odourless powder’.
Dr James McIlroy, chief executive officer of EnteroBiotix, commented: “We are excited to have achieved this important milestone in our quest to alleviate the suffering caused by IBS. We believe that EBX-102-02 has the potential to be transformational for the IBS patient community and for the field of microbiome therapeutics. We look forward to working in collaboration with our partners to take us closer to realising our vision of tackling unmet clinical needs with best-in-class full-spectrum microbiome medicines.”
Betsy Goodfellow
Related Content
Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults
NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to …
Bausch Health buy bankrupt Synergy Pharmaceuticals for $200m
Bankrupt drug developer Synergy Pharmaceuticals has announced that the company is to be acquired by …
Immune system exhaustion associated with irritable bowel syndrome
Researchers from the University of Adelaide have linked a specific type of irritable bowel syndrome …
